<DOC>
	<DOCNO>NCT01129778</DOCNO>
	<brief_summary>The purpose research study ass safe , effective ( well work ) , tolerable ( put ) drug Zegerid reduce reflux episode patient gastroesophageal reflux disease ( GERD ) Barrett 's esophagus . Zegerid approve US Food Drug Administration ( FDA ) treatment GERD . The investigator hope learn effectiveness Zegerid reduce amount acid reflux patient experience esophagus ( swallow pipe ) .</brief_summary>
	<brief_title>Assessment Zegerid Esophageal pH Patients With Barrett 's Esophagus</brief_title>
	<detailed_description>The following procedure perform Screening Visit : - Obtain informed consent . - Obtain information age gender . - Evaluate whether qualify study . - Document prior negative test H. pylori infection ( bacterial infection stomach cause ulcer ) include date testing . - Make sure use investigational medication participate clinical trial 30 day prior Screening Visit . - Obtain medical history . - Record medication history ( include concomitant medication ) . - Obtain vital sign . - Conduct physical examination . - If Bravo pH study do within 8 week , instruct patient discontinue medication GERD 7-10 day washout period . - Instruct patient discontinue use prohibit medication applicable time interval start new concomitant medication trial . - Distribute Gelusil tablet use `` rescue medication '' ; instruct patient 6 Gelusil tablet per day 21 tablet 7-day interval allow . - Schedule patient return Qualification Visit , pH monitoring Qualification Visit . Only patient abnormal pH monitoring able enter treatment period . Procedures occur Treatment Period : - You receive Zegerid 1 hour breakfast bedtime least 14 day longer 28 day - At end Zegerid treatment period , undergo 48-hour Bravo pH monitor Zegerid therapy two day . You complete symptom survey quality life survey completion pH study .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Omeprazole , sodium bicarbonate drug combination</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Inclusion criterion include adult men woman ( age &amp; # 8805 ; 18 year ) previously establish , biopsyproven diagnosis BE ( length intestinal metaplasia without dysplasia adenocarcinoma ) Exclusion criterion include history esophageal , gastric , duodenal surgery ( include antireflux surgery endoscopic antireflux procedure ) , except simple ulcer closure ZollingerEllison syndrome Endoscopic evidence suspicion pathologic infiltrative process stomach Positive H. pylorus .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>